[EN] CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS [FR] DÉRIVÉS DE DIARYLBORON CYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'INFLAMMASOME NLRP3
[EN] CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS [FR] DÉRIVÉS DE DIARYLBORON CYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'INFLAMMASOME NLRP3
Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome
作者:Alex G. Baldwin、Victor S. Tapia、Tessa Swanton、Claire S. White、James A. Beswick、David Brough、Sally Freeman
DOI:10.1002/cmdc.201700731
日期:2018.2.20
gout, atherosclerosis, type II diabetes and Alzheimer's disease. In this study, we report the design, synthesis and biological evaluation of novel boron compounds (NBCs) as NLRP3 inflammasome inhibitors. Structure-activity relationships (SAR) show that 4-fluoro substituents on the phenyl rings retain NLRP3 inhibitory activity, whereas more steric and lipophilic substituents diminish activity. Loss of
Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors
申请人:The University of Manchester
公开号:US10570157B2
公开(公告)日:2020-02-25
Inhibitor compounds are disclosed. The compounds are effective in the treatment of diseases or conditions in which interleukin 1 β activity is implicated. Methods of synthesis of the compounds, as well as pharmaceutical compositions comprising the compounds are also disclosed.